Table 3 The completed and recruiting clinical trials of virus-related HCC
From: Viral oncogenesis in cancer: from mechanisms to therapeutics
Conditions | Interventions | Phases | Patients (N) | NCT number | Status | Study period | URL |
|---|---|---|---|---|---|---|---|
HBV+ redirected HCC | mRNA HBV/TCR T-cells | PHASE1 | 10 | NCT04745403 | RECRUITING | 2022/5/20 −2028/7/1 | |
HBV+ advanced HCC | Atezolizumab bevacizumab | NA | 51 | NCT04180072 | ACTIVE_NOT_RECRUITING | 2020/3/12 −2025/12/31 | |
HBV+ advanced HCC | HBV-TCR T Cells (LioCyx-M) | PHASE1|PHASE2 | 55 | NCT05195294 | NOT_YET_RECRUITING | 2022/6/1 2027/5/1 | |
HBV+ advanced HCC | HBV mRNA vaccine | PHASE1 | 9 | NCT05738447 | RECRUITING | 2023/2/15 −2025/1/1 | |
HBV+ advanced HCC | Durvalumab | PHASE2 | 43 | NCT04294498 | RECRUITING | 2020/11/2 −2025/12/31 | |
HBV+ HCC | Hepatect CP 50 I.E./ml infusion solution | NA | 5 | NCT05293158 | NOT_YET_RECRUITING | 2024/11/1 −2026/6/1 | |
HBV+ HCC | pembrolizumab | PHASE2 | 30 | NCT03419481 | ACTIVE_NOT_RECRUITING | 2018/4/30 −2025/12/30 | |
HBV+ Advanced or Metastatic HCC | Lenvatinib tislelizumab | PHASE2 | 30 | NCT05897138 | NOT_YET_RECRUITING | 2023/8/1 −2027/6/1 | |
HBV+ HCC | Biological: SCG101 | PHASE1|PHASE2 | 46 | NCT05417932 | RECRUITING | 2022/10/26 −2025/10/1 | |
HBV+ High Risk of HCC | Peginterferon alfa-2b Injection, Nucleos (t) ide Analog | NA | 267 | NCT05671315 | RECRUITING | 2019/7/3 −2026/4/1 | |
HBV+ Advanced HCC | MTL-CEBPA Sorafenib | PHASE2 | 150 | NCT04710641 | ACTIVE_NOT_RECRUITING | 2022/1/1 −2025/5/1 |
